Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

13 juil. 2026 10h30 HE | Source: Custom Market Insights

[Latest] Global Sodium-ion Battery Market Size/Share Worth USD 1846 Million by 2035 at a 11.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, July 13, 2026 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Sodium-ion Battery Market Size, Trends and Insights By Type (Refurbished Phones,...
09 juil. 2026 23h30 HE | Source: Custom Market Insights

[Latest] Global Lithium-Ion Battery Market Size/Share Worth USD 468.5 Billion by 2035 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, July 10, 2026 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Lithium-Ion Battery Market Size, Trends and Insights By Product (Lithium cobalt...
04 févr. 2026 07h00 HE | Source: Oxford Biomedica Solutions LLC

OXB Signs New Multi-Year Commercial Supply Agreement with Bristol Myers Squibb

OXB to become commercial manufacturer of lentiviral vectors for Bristol Myers Squibb (BMS) CAR-T programmesMulti-year agreement with five-year initial term and option to extend Oxford, UK – 4...
09 déc. 2025 07h00 HE | Source: BioNTech SE

Erste Ergebnisse aus BioNTechs und BMS’ globaler Phase-2-Studie mit bispezifischem PD-L1xVEGF-A-Antikörperkandidat Pumitamig zeigten ermutigende Anti-Tumor-Aktivität bei fortgeschrittenem dreifach negativem Brustkrebs

Zwischenergebnisse der globalen klinischen Phase-2-Studie bei lokal fortgeschrittenem/metastasiertem dreifach negativem Brustkrebs (triple-negative breast cancer, „TNBC“) zeigten eine ermutigende...
09 déc. 2025 07h00 HE | Source: BioNTech SE

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer

Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer (”TNBC”) show encouraging antitumor activity for investigational therapy pumitamig (BNT327/BMS986545) plus...
09 oct. 2025 07h07 HE | Source: Research and Markets

Global and China High-Voltage Power Supply in New Energy Vehicle (BMS, BDU, Relay, Integrated Battery Box) Research Report 2025: The Shift of BMS from Centralized to Distributed Architectures

Dublin, Oct. 09, 2025 (GLOBE NEWSWIRE) -- The "High-Voltage Power Supply in New Energy Vehicle (BMS, BDU, Relay, Integrated Battery Box) Research Report, 2025" report has been added to ...
18 sept. 2025 09h00 HE | Source: Applied Systems

Applied Remains the Industry’s Leading Provider of Agency Management Systems According to Multiple Industry Lists

Chicago, IL., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Applied Systems® today announced more agencies are leveraging an Applied agency management system than any other system among the largest agencies in...
08 sept. 2025 11h00 HE | Source: BioNTech SE

Erste Zwischenergebnisse aus BioNTechs und BMS‘ globaler Phase-2-Studie mit bispezifischem PD-L1xVEGF-A-Antikörperkandidat Pumitamig (BNT327/BMS986545) zeigen ermutigende Anti-Tumor-Aktivität bei fortgeschrittenem kleinzelligem Lungenkrebs

Daten zur Kombination des bispezifischen PD-L1xVEGF-A-Antikörper-Kandidaten Pumitamig (BNT327/BMS986545) mit Chemotherapie zeigen weiterhin ermutigende Anti-Tumor-Aktivitäten bei Patientinnen und...
08 sept. 2025 11h00 HE | Source: BioNTech SE

First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity

PD-L1xVEGF-A bispecific antibody pumitamig (BNT327/BMS986545) plus chemotherapy continues to show encouraging antitumor activity in patients with extensive-stage small cell lung cancer (”ES-SCLC”),...
04 juin 2025 12h50 HE | Source: Spherix Global Insights

As Interest Grows for New Agents to Treat Thalassemia, Hematologists Begin Early Identification of Ideal Patients for Gene Therapies Vs. New Therapeutic Options

EXTON, PA, June 04, 2025 (GLOBE NEWSWIRE) -- Despite the promise of new curative strategies for beta thalassemia, such as Casgevy (Vertex) and Zynteglo (bluebird bio), most transfusion-dependent...

Page suivante